CN117098547A - 适用于新生儿的组合物 - Google Patents

适用于新生儿的组合物 Download PDF

Info

Publication number
CN117098547A
CN117098547A CN202180071124.7A CN202180071124A CN117098547A CN 117098547 A CN117098547 A CN 117098547A CN 202180071124 A CN202180071124 A CN 202180071124A CN 117098547 A CN117098547 A CN 117098547A
Authority
CN
China
Prior art keywords
weeks
composition
months
igf
polysorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180071124.7A
Other languages
English (en)
Chinese (zh)
Inventor
N•萨拉马特-米勒
K·泰勒
何冰
I·巴塔查里亚
韩琳达
B·阿姆斯登
J·克兰恩泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oakhill Biology Co ltd
Original Assignee
Oakhill Biology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oakhill Biology Co ltd filed Critical Oakhill Biology Co ltd
Publication of CN117098547A publication Critical patent/CN117098547A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180071124.7A 2020-10-19 2021-10-19 适用于新生儿的组合物 Pending CN117098547A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063093696P 2020-10-19 2020-10-19
US63/093,696 2020-10-19
PCT/US2021/055598 WO2022086953A1 (en) 2020-10-19 2021-10-19 Compositions suitable for use in neonates

Publications (1)

Publication Number Publication Date
CN117098547A true CN117098547A (zh) 2023-11-21

Family

ID=78622033

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180071124.7A Pending CN117098547A (zh) 2020-10-19 2021-10-19 适用于新生儿的组合物

Country Status (24)

Country Link
US (1) US20230381285A1 (cg-RX-API-DMAC10.html)
EP (2) EP4228676B1 (cg-RX-API-DMAC10.html)
JP (2) JP7827315B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230113287A (cg-RX-API-DMAC10.html)
CN (1) CN117098547A (cg-RX-API-DMAC10.html)
AU (1) AU2021364523A1 (cg-RX-API-DMAC10.html)
CA (1) CA3194764A1 (cg-RX-API-DMAC10.html)
DK (1) DK4228676T3 (cg-RX-API-DMAC10.html)
ES (1) ES3005966T3 (cg-RX-API-DMAC10.html)
FI (1) FI4228676T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20250193T1 (cg-RX-API-DMAC10.html)
HU (1) HUE070409T2 (cg-RX-API-DMAC10.html)
IL (1) IL301688A (cg-RX-API-DMAC10.html)
LT (1) LT4228676T (cg-RX-API-DMAC10.html)
MX (1) MX2023004426A (cg-RX-API-DMAC10.html)
PL (1) PL4228676T3 (cg-RX-API-DMAC10.html)
PT (1) PT4228676T (cg-RX-API-DMAC10.html)
RS (1) RS66493B1 (cg-RX-API-DMAC10.html)
SA (1) SA523440271B1 (cg-RX-API-DMAC10.html)
SI (1) SI4228676T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202500093T1 (cg-RX-API-DMAC10.html)
TW (1) TWI912393B (cg-RX-API-DMAC10.html)
WO (1) WO2022086953A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202303162B (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250099541A1 (en) 2022-01-19 2025-03-27 Oak Hill Bio Ltd Compositions and methods for reducing oxidation of igf-1/igfbp
CA3248280A1 (en) 2022-05-04 2023-11-09 Oak Hill Bio Limited POLYTHERAPY FOR PREMATURE INFANTS
WO2023242439A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Vascular stabilisation (preterm infants)
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
EP4598630A1 (en) * 2022-10-04 2025-08-13 Oak Hill Bio Limited Method of treating neonates with igf-1 complex

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1315868A (zh) * 1998-06-01 2001-10-03 谢尔特里克斯药品公司 Igf/igfbp的药用制剂
US20020028764A1 (en) * 2000-09-04 2002-03-07 Aarhus Amt. Treatment of acute and chronic liver disease
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20120270782A1 (en) * 2009-11-17 2012-10-25 Ipsen Pharma S.A.S. Formulation for hgh and rhigf-1 combination
US20140199286A1 (en) * 2013-01-15 2014-07-17 Teva Pharmaceutical Industries, Ltd. Lyophilization process
US20190151411A1 (en) * 2017-09-11 2019-05-23 Shire Human Genetic Therapies, Inc. Methods and compositions for treating chronic lung diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
ATE90690T1 (de) 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
EP0639981A4 (en) 1992-05-08 1995-06-28 Univ Jefferson ANALOGS OF THE IGF FACTOR (01/18/94).
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
EP0956041A1 (en) * 1996-09-16 1999-11-17 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
JP2008543839A (ja) * 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
KR20140119396A (ko) * 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
US20250099541A1 (en) * 2022-01-19 2025-03-27 Oak Hill Bio Ltd Compositions and methods for reducing oxidation of igf-1/igfbp
WO2023139250A1 (en) * 2022-01-24 2023-07-27 Oak Hill Bio Limited Lot release assays for igf‐1/igfbp complexes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1315868A (zh) * 1998-06-01 2001-10-03 谢尔特里克斯药品公司 Igf/igfbp的药用制剂
US20020028764A1 (en) * 2000-09-04 2002-03-07 Aarhus Amt. Treatment of acute and chronic liver disease
US20120270782A1 (en) * 2009-11-17 2012-10-25 Ipsen Pharma S.A.S. Formulation for hgh and rhigf-1 combination
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20140199286A1 (en) * 2013-01-15 2014-07-17 Teva Pharmaceutical Industries, Ltd. Lyophilization process
US20190151411A1 (en) * 2017-09-11 2019-05-23 Shire Human Genetic Therapies, Inc. Methods and compositions for treating chronic lung diseases

Also Published As

Publication number Publication date
PT4228676T (pt) 2025-01-24
JP2026102579A (ja) 2026-06-23
SMT202500093T1 (it) 2025-03-12
IL301688A (en) 2023-05-01
WO2022086953A9 (en) 2022-07-07
AU2021364523A1 (en) 2023-04-06
JP2023550203A (ja) 2023-11-30
ES3005966T3 (en) 2025-03-17
MX2023004426A (es) 2023-08-04
LT4228676T (lt) 2025-02-10
HUE070409T2 (hu) 2025-06-28
HRP20250193T1 (hr) 2025-04-11
SA523440271B1 (ar) 2025-04-10
EP4534073A2 (en) 2025-04-09
EP4228676A1 (en) 2023-08-23
US20230381285A1 (en) 2023-11-30
SI4228676T1 (sl) 2025-03-31
WO2022086953A1 (en) 2022-04-28
TWI912393B (zh) 2026-01-21
KR20230113287A (ko) 2023-07-28
FI4228676T3 (fi) 2025-02-26
CA3194764A1 (en) 2022-04-28
EP4534073A3 (en) 2025-05-14
RS66493B1 (sr) 2025-03-31
DK4228676T3 (da) 2025-01-20
PL4228676T3 (pl) 2025-04-07
EP4228676B1 (en) 2025-01-08
JP7827315B2 (ja) 2026-03-10
ZA202303162B (en) 2024-08-28
TW202233228A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
TWI912393B (zh) 適用於新生兒的組成物
US8518877B2 (en) Method and product for treatment and/or prevention of complications of prematurity
AU2024227601B2 (en) Methods and compositions for treating chronic lung diseases
EA049095B1 (ru) Композиции, подходящие для применения у новорожденных
HK40099225B (en) Compositions suitable for use in neonates
HK40099225A (en) Compositions suitable for use in neonates
US20090181882A1 (en) Methods and preparations for curing critically ill patients
EA044079B1 (ru) Способы и композиции, предназначенные для лечения хронических заболеваний легких
HK40033881A (en) Methods and compositions for treating chronic lung diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination